

## Developing new therapies for Batten disease

Batten disease or Neuronal Ceroid Lipofuscinoses (NCL) is a life-limiting neurodegenerative disease for which there is currently no cure.

### What is BATCure?

BATCure is a 3-year research project funded under a European Union call (New Therapies for Rare Diseases). The goal of the project is to advance the development of new therapeutic options for patients and their families living with CLN 3, 6 or 7 Batten disease.

### Who is involved?

A consortium from seven European countries made up of ten leading scientific research groups, three companies and the Batten Disease Family Association (BDFa) who is leading part of the project and ensuring that the voice of patients and affected families is heard.



The BATCure project focuses on the most prevalent type of NCL, CLN3 (Juvenile Batten Disease or JNCL), CLN6 and CLN7 diseases.

### BATCure Coordinator

**Professor Sara E Mole**  
MRC Laboratory for Molecular Cell Biology,  
UCL Institute of Child Health and  
Department of Genetics,  
Evolution & Environment, University College London  
[s.mole@ucl.ac.uk](mailto:s.mole@ucl.ac.uk)

### BDFa Project Contact

**Laura Codd**  
BATCure Administrator - BDFa  
[lauracodd@bdfa-uk.org.uk](mailto:lauracodd@bdfa-uk.org.uk)  
[www.bdfa-uk.org.uk](http://www.bdfa-uk.org.uk)



BATCure

[www.batcure.eu](http://www.batcure.eu)

@BAT\_Cure



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 666918